917111-44-5

Basic information

• Product Name: CYT997
• Synonyms: CYT997;N-Ethyl-N'-[2-methoxy-4-[5-methyl-4-[[(1S)-1-(3-pyridinyl)butyl]amino]-2-pyrimidinyl]phenyl]urea;CYT997 (Lexibulin);Lexibulin;1-ethyl-3-(2-methoxy-4-(5-methyl-4-((S)-1-(pyridin-3-yl)butylamino)pyrimidin-2-yl)phenyl)urea;CYT 997 N-Ethyl-N'-[2-methoxy-4-[5-methyl-4-[[(1S)-1-(3-pyridinyl)butyl]amino]-2-pyrimidinyl]phenyl]urea;N-Ethyl-N'-[2-methoxy-4-[5-methyl-4-[[(1S)-1-(3-pyridinyl)butyl]amino]-2-pyrimidinyl]phenyl]urea CYT997 (Lexibulin);Lexibulin(CYT-997)
• CAS NO: 917111-44-5
• Molecular Formula: C₂₄H₃₀N₆O₂
• Molecular Weight: 434.55
• EINECS: -0
• Product Categories: Inhibitors
• Mol File: 917111-44-5.mol

Chemical Properties

• Boiling Point: 546.9±50.0 °C(Predicted)
• Appearance: /
• Density: 1.195
• PKA: 14.01±0.70(Predicted)
• CAS DataBase Reference: CYT997(CAS DataBase Reference)
• NIST Chemistry Reference: CYT997(917111-44-5)
• EPA Substance Registry System: CYT997(917111-44-5)

Safety Data

• Hazardous Substances Data: 917111-44-5(Hazardous Substances Data)

Upstream product

• 854074-39-8 2-chloro-5-methyl-N-[(1S)-1-pyridin-3-ylbutyl]pyrimidin-4-amine 
• 917111-46-7 1-ethyl-3-[2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)phenyl]urea 

Downstream Products

• 917111-49-0 N-ethyl-N'-[2-methoxy-4-(5-methyl-4-{[(1S)-1-pyridin-3-ylbutyl]amino}pyrimidin-2-yl)phenyl]urea dihydrochloride 
• 917111-47-8 N-ethyl-N'-[2-methoxy-4-(5-methyl-4-{[(1S)-1-pyridin-3-ylbutyl]amino}pyrimidin-2-yl)phenyl]urea citrate 
• 917111-53-6 N-ethyl-N'-[2-methoxy-4-(5-methyl-4-{[(1S)-1-pyridin-3-ylbutyl]amino}pyrimidin-2-yl)phenyl]urea oxalate 

Relevant articles and documents

Discovery of CYT997: a structurally novel orally active microtubule targeting agent

CYT997 was discovered as a potent tubulin polymerization inhibitor possessing potent cytotoxic activity against a range of cancer cells. Details of SAR studies, pharmacokinetic investigations and synthesis of compounds leading to the discovery of CYT997 a

TUBULIN INHIBITORS

Compounds of general formula (I), (II) (III) and (V) are described for use in modulating microtubule polymerisation and in the treatment of associated disease states. Use of compounds (I), (III) and (V) in the treatment of kinase-associated disease states is also described. Further described are novel compounds of formula (II), (III) and (V).